World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
73
Citations
24301
World Ranking
2108
National Ranking
53

Overview

Alexandra Trkola is affiliated with the University of Zurich in Switzerland. Their research spans multiple fields within medicine, particularly focusing on infectious diseases, virology, epidemiology, emergency medicine, and immunology.

The main topics of their work include the study and treatment of viral infections such as HIV and SARS-CoV-2. Key areas of focus are:

  • SARS-CoV-2 and COVID-19 Research
  • HIV Research and Treatment
  • HIV/AIDS Research and Interventions
  • HIV-related health complications and treatments
  • HIV/AIDS drug development and treatment
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 detection and testing

Frequently collaborating with other researchers, Alexandra Trkola has worked extensively with colleagues including:

  • Huldrych F. Günthard
  • Roger D. Kouyos
  • Enos Bernasconi
  • Matthias Cavassini
  • Dominique L. Braun

Their research outputs have been published in a variety of journals. The most frequent publication venues are:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Clinical Infectious Diseases
  • The Journal of Infectious Diseases
  • Open Forum Infectious Diseases
  • Journal of Antimicrobial Chemotherapy

Some notable recent papers authored by or associated with Alexandra Trkola include:

  • "Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2" (2020, mBio)
  • "Cohort Profile Update: The Swiss HIV Cohort Study (SHCS)" (2021, International Journal of Epidemiology)
  • "Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools" (2021, BMJ)
  • "A highly virulent variant of HIV-1 circulating in the Netherlands" (2022, Science)
  • "SARS-CoV-2 variants reveal features critical for replication in primary human cells" (2021, PLoS Biology)

Best Publications

  • CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

    Alexandra Trkola;Tatjana Dragic;James Arthos;James M. Binley

  • Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

    A Trkola;M Purtscher;T Muster;C Ballaun

  • A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

    T Muster;F Steindl;M Purtscher;A Trkola

  • Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.

    A. Buchacher;R. Predl;K. Strutzenberger;W. Steinfellner

  • Co-receptors for HIV-1 entry.

    John P Moore;Alexandra Trkola;Tatjana Dragic

  • Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

    Alexandra Trkola;Herbert Kuster;Peter Rusert;Beda Joos

  • Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

    A Trkola;A B Pomales;H Yuan;B Korber

  • A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

    Tatjana Dragic;Alexandra Trkola;Daniah A. D. Thompson;Emmanuel G. Cormier

  • SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

    Julie M. Strizki;Serena Xu;Nicole E. Wagner;Lisa Wojcik

  • A Broadly Neutralizing Human Monoclonal Antibody against gp41 of Human Immunodeficiency Virus Type 1

    Martin Purtscher;Alexandra Trkola;Gerhard Gruber;Andrea Buchacher

  • HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

    Alexandra Trkola;Shawn E. Kuhmann;Julie M. Strizki;Elizabeth Maxwell

  • Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS

    T Muster;R Guinea;A Trkola;M Purtscher

  • Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.

    T R Fouts;J M Binley;A Trkola;J E Robinson

  • HIV rebounds from latently infected cells, rather than from continuing low-level replication.

    Beda Joos;Marek Fischer;Herbert Kuster;Satish K. Pillai

  • Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140

    Alexandra Trkola;Thomas J. Ketas;Kirsten A. Nagashima;Lu Zhao

  • Amino-Terminal Substitutions in the CCR5 Coreceptor Impair gp120 Binding and Human Immunodeficiency Virus Type 1 Entry

    Tatjana Dragic;Alexandra Trkola;Steven W. Lin;Kirsten A. Nagashima

  • The BBXB Motif of RANTES Is the Principal Site for Heparin Binding and Controls Receptor Selectivity

    Amanda E.I. Proudfoot;Sarah Fritchley;Frédéric Borlat;Jeffrey P. Shaw

  • Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry

    Fotini Tsamis;Svetlana Gavrilov;Francis Kajumo;Christoph Seibert

  • Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines

    R. I. Connor;B. T. M. Korber;B. S. Graham;B. H. Hahn

  • HIV-1–specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

    Gabriel M. Ortiz;Douglas F. Nixon;Alexandra Trkola;James Binley

Frequent Co-Authors

Huldrych F. Günthard
Huldrych F. Günthard University of Zurich
Michael Huber
Michael Huber University of Zurich
John P. Moore
John P. Moore Cornell University
Jürg Böni
Jürg Böni University of Zurich
Hermann Katinger
Hermann Katinger BOKU University
Rainer Weber
Rainer Weber University of Zurich
Marek Fischer
Marek Fischer University of Zurich
Roger D. Kouyos
Roger D. Kouyos University of Zurich
Karin J. Metzner
Karin J. Metzner University of Zurich
Stefan Schmutz
Stefan Schmutz BOKU University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those pursuing a career in Immunology in the USA, expanding your qualifications through related nursing degrees can open diverse opportunities. Many students transition from foundational nursing roles to more specialized ones, such as moving from Family Nurse Practitioner (FNP) roles to advanced clinical positions. Programs like the fnp to acute care np bridge program help facilitate this critical career shift efficiently.

If you’re an RN looking to advance quickly, exploring accelerated rn to np programs offers an expedited pathway to becoming a nurse practitioner. These programs blend rigorous coursework with clinical experience tailored to enhance your practice in immunology-related fields.

For those entering nursing from non-nursing backgrounds, online absn programs for non nurses provide accessible routes to build foundational knowledge and skills while balancing other commitments. Likewise, choosing among the easiest absn program to get into can make your transition smoother and more manageable.

Whether you are deepening your expertise or changing your professional trajectory, these pathways offer flexibility and growth essential for success in Immunology and healthcare careers.

Best Scientists Citing Alexandra Trkola

Trending Scientists